Porter, MD
David W. Porter, Annapolis, MD US
Forbes Porter, Gaithersburg, MD US
Patent application number | Description | Published |
---|---|---|
20130177990 | METHODS OF DETERMINING EFFICACY OF CYCLODEXTRIN THERAPY - Disclosed are methods for determining efficacy of a cyclodextrin therapy in a subject afflicted with a disorder involving oxysterol accumulation. These methods comprise: obtaining a first body fluid sample from the subject prior to cyclodextrin administration; administering cyclodextrin; obtaining at least one second body fluid sample after the cyclodextrin administration; subjecting the body fluid samples to chromatography-mass spectroscopy analysis to determine concentration of 24-hydroxycholesterol and/or cholestane-3β,5α,6β-triol; and determining magnitude of difference between the 24-hydroxycholesterol and/or cholestane-3β,5α,6β-triol concentration of the body fluid samples, whereby an increase or stabilization of 24-hydroxycholesterol concentration, or a reduction of cholestane-3β,5α,6β-triol concentration in the at least one second sample compared to the first sample, indicates efficacy of the cyclodextrin therapy. | 07-11-2013 |
Forbes D. Porter, Bethesda, MD US
Patent application number | Description | Published |
---|---|---|
20140024632 | METHODS FOR TREATMENT OF AUTISM SPECTRUM DISORDER - The present invention relates to the field of autism. More specifically, the present invention provides methods for treating individuals with autism spectrum disorder. Accordingly, in one aspect, the present invention provides methods for treating patients with autism spectrum disorder. In one embodiment, a method for treating an autism spectrum disorder (ASD) in a patient comprises the step of administering a therapeutically effective amount of cholesterol to the patient. In more specific embodiments, the ASD is autism, Asperger's disorder, pervasive developmental disorder-not otherwise specified (PDD-NOS), Rett's syndrome and childhood disintegrative disorder. In one embodiment, the patient has autism. | 01-23-2014 |
Forbes D. Porter, Gaithersburg, MD US
Patent application number | Description | Published |
---|---|---|
20090286272 | Biomarkers for niemann-pick C disease and related disorders - Methods for screening or diagnosing subjects for disorders involving accumulation of one or more oxysterols such as cytotoxic oxysterol accumulation, Niemann-Pick C(NPC) disease, lysosomal storage diseases, cholesterol trafficking diseases, and neurodegenerative diseases. Also provided are methods for methods for screening or diagnosing subjects (including infants and neonatal subjects) for NPC disease, methods for monitoring the progression, remission, and clinical status of NPC disease, and methods for evaluating the efficacy of therapeutic treatment of NPC disease. | 11-19-2009 |
Forbes Dennison Porter, Bethesda, MD US
Patent application number | Description | Published |
---|---|---|
20100204162 | SUBSTRATE REDUCTION THERAPY - The present invention provides a compound which is an inhibitor of sphingolipid biosynthesis for use in the treatment of a disease which has a secondary Niemann-Pick type C disease like cellular phenotype. | 08-12-2010 |
20140080769 | SUBSTRATE REDUCTION THERAPY - The present invention provides a compound which is an inhibitor of sphingolipid biosynthesis for use in the treatment of a disease which has a secondary Niemann-Pick type C disease like cellular phenotype. | 03-20-2014 |
Jerry Porter, Kensington, MD US
Patent application number | Description | Published |
---|---|---|
20110168703 | Limited Flow Cup - Limited flow cups are provided which deliver a metered amount of fluid to a user during a drinking motion. | 07-14-2011 |
Kevin Porter, Boyds, MD US
Patent application number | Description | Published |
---|---|---|
20110014233 | PSORALEN-INACTIVATED VIRAL VACCINE AND METHOD OF PREPARATION - A method to prepare inactivate viral vaccine by exposing the virus to a predetermined concentration of an inactivating psoralen, and a preselected intensity of ultraviolet radiation for a time period sufficiently long to render the virus non-infectious but less than that which would result in degradation of its antigenic characteristics. | 01-20-2011 |
Kevin R. Porter, Boyds, MD US
Patent application number | Description | Published |
---|---|---|
20080219930 | Method for the evaluation of dengue virus therapeutic agents - The inventive subject matter relates to a method for evaluating potential compounds and vaccines for the prevention or treatment of dengue virus infection. The method utilizes pigs as an animal model for the evaluation of test vaccine or drug compounds. The breeds that can be utilized and in the inventive method include Yorkshire or Lancashire as well as miniature pig breeds. | 09-11-2008 |
20120135035 | Induction of an immune response against dengue virus using the prime-boost approach - The invention relates to methods for the induction of an immune response to dengue virus. The method of inducing an immune response against dengue virus comprises administration of a non-replicating immunogen followed by a boost with a tetravalent live attenuated viral vaccine. Another aspect of the inventive subject matter is a method of inducing an immune response against dengue virus using a heterologous prime-boost regimen with the priming immunogen comprising a DNA expression system, an adenovirus expression vector or a Venezuelan equine encephalitis virus replicon system and the boosting immunogen comprising the same without the DNA expression system. Each expression system contains DNA sequences encoding dengue viral proteins. | 05-31-2012 |
20140271714 | INDUCTION OF AN IMMUNE RESPONSE AGAINST DENGUE VIRUS USING THE PRIME-BOOST APPROACH - The invention relates to methods for the induction of an immune response to dengue virus. The method of inducing an immune response against dengue virus comprises administration of a non-replicating immunogen followed by a boost with a tetravalent live attenuated viral vaccine. Another aspect of the inventive subject matter is a method of inducing an immune response against dengue virus using a heterologous prime-boost regimen with the priming immunogen comprising a DNA expression system, an adenovirus expression vector or a Venezuelan equine encephalitis virus replicon system and the boosting immunogen comprising the same without the DNA expression system. Each expression system contains DNA sequences encoding dengue viral proteins. | 09-18-2014 |
Larry Porter, Owings Mills, MD US
Patent application number | Description | Published |
---|---|---|
20110112946 | System for online lending services via an application service provider network - A method for online lending services with the creation and population of loan applications and other related documents in Portable Document Format (PDF) for subsequent access by applicant and other entities. Consumers use their Web browsers for access and said method includes an Application Service Provider (ASP) architecture, a loan origination site interface, and a secure server facility. | 05-12-2011 |
20140082004 | SYSTEM FOR ONLINE LENDING SERVICES VIA AN APPLICATION SERVICE PROVIDER NETWORK - A method for online lending services with the creation and population of loan applications and other related documents in Portable Document Format (PDF) for subsequent access by application and other entities. Consumers use their Web browsers for access and said method includes an Application Service Provider (ASP) architecture, a loan origination site interface, and a secure server facility. | 03-20-2014 |
Mark Porter, Gaithersburg, MD US
Patent application number | Description | Published |
---|---|---|
20090220970 | MOLECULAR TOXICOLOGY MODELING - The present invention is based on the elucidation of the global changes in gene expression and the identification of toxicity markers in tissues or cells exposed to a known toxin. The genes may be used as toxicity markers in drug screening and toxicity assays. The invention includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes. | 09-03-2009 |
20110071767 | Hepatotoxicity Molecular Models - The present invention includes methods of predicting hepatotoxicity of test agents and methods of generating hepatotoxicity prediction models using algorithms for analyzing quantitative gene expression information. The invention also includes microarrays, computer systems comprising the toxicity prediction models, as well as methods of using the computer systems by remote users for determining the toxicity of test agents. | 03-24-2011 |
Mark W. Porter, Germantown, MD US
Patent application number | Description | Published |
---|---|---|
20080215250 | Molecular toxicology modeling - The present invention is based on the elucidation of the global changes in gene expression and the identification of toxicity markers in tissues or cells exposed to a known toxin. The genes may be used as toxicity markers in drug screening and toxicity assays. The invention includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes. | 09-04-2008 |
Mark W. Porter, Gaithersburg, MD US
Patent application number | Description | Published |
---|---|---|
20090197258 | PRIMARY RAT HEPATOCYTE TOXICITY MODELING - The present invention is based on the elucidation of the global changes in gene expression and the identification of toxicity markers in tissues or cells exposed to a known toxin. The genes may be used as toxicity markers in drug screening and toxicity assays. The invention includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes. | 08-06-2009 |
Michael Porter, Baltimore, MD US
Patent application number | Description | Published |
---|---|---|
20110059455 | METHODS AND COMPOSITIONS FOR DIRECT CHEMICAL LYSIS - A direct chemical lysis composition includes an assay compatible buffer composition and an assay compatible surfactant. When combined with a specimen storage composition, such compositions prevent undesired modifications to nucleic acid and proteins lysed from cells in the biological sample. Assays of samples from such compositions do not require expensive and time-consuming steps such as centrifugation and prolonged high temperature processing. The direct chemical lysis composition of the present invention permits direct nucleic acid extraction from the cells in the biological sample without the need to decant off the transport media or otherwise exchange the transport media with assay compatible buffers. There is no need to combine the sample with proteinase K or another enzyme to extract nucleic acids from the cells. A method for lysing cells to obtain target nucleic acid for assay and a kit for combining the direct chemical lysis composition with a sample are also contemplated. | 03-10-2011 |
20110201516 | ASSAY FOR DETECTING CLOSELY-RELATED SEROTYPES OF HUMAN PAPILLOMAVIRUS (HPV) - A real time Taq-Man PCR assay for detecting multiple serotypes of human papillomavirus (HPV) wherein the number of serotypes detected exceeds the number of colorimetric channels for detection. A biological sample is combined with three oligonucleotide primer/probe sets such that the probes and primers anneal to a target sequence. Each primer/probe set is at least preferential for a specific serotype of an organism. The first and second primer/probe sets are degenerate with respect to each other. The third primer/probe set is not degenerate with respect to the first and second primer/probe sets and discriminates for a third serotype. The third primer/probe set has a signal moiety that emits signal at a wavelength that is the same or different from the wavelength emitted by the signal moiety of the degenerate primer/probe set probes. The target sequences, if present, are amplified and detected. | 08-18-2011 |
20140256580 | ASSAY FOR DETECTING CLOSELY-RELATED SEROTYPES OF HUMAN PAPILLOMAVIRUS (HPV) - A real time Taq-Man PCR assay for detecting multiple serotypes of human papillomavirus (HPV) wherein the number of serotypes detected exceeds the number of colorimetric channels for detection. A biological sample is combined with three oligonucleotide primer/probe sets such that the probes and primers anneal to a target sequence. Each primer/probe set is at least preferential for a specific serotype of an organism. The first and second primer/probe sets are degenerate with respect to each other. The third primer/probe set is not degenerate with respect to the first and second primer/probe sets and discriminates for a third serotype. The third primer/probe set has a signal moiety that emits signal at a wavelength that is the same or different from the wavelength emitted by the signal moiety of the degenerate primer/probe set probes. The target sequences, if present, are amplified and detected. | 09-11-2014 |
Riley Porter, Silver Spring, MD US
Patent application number | Description | Published |
---|---|---|
20100251375 | METHOD AND APPARATUS FOR MINIMIZING NETWORK VULNERABILITY - An apparatus, system, and method for controlling access to a network. A device controls communication between a computer and the network. The device includes an integrated circuit receiving signals from one or more peripheral devices and transmitting the received signals to the computer, a first data connection connecting the computer to the device, and a second data connection connecting the apparatus to a network. The device also includes a switch connecting the first and second data connections and permitting the computer to access the network when in a first state and disconnecting the first and second data connections when in a second state. The device further includes a timer determining the time period since the last transmission of signals from the one or more peripheral devices, and when the time period since the last transmission of signals exceeds a predetermined time period the integrated circuit causes the switch to change from the first state to the second state. | 09-30-2010 |
20120079563 | METHOD AND APPARATUS FOR MINIMIZING NETWORK VULNERABILITY VIA USB DEVICES - A device for preventing the rewriting and revision of the firmware installed on one or more USB devices, the device including a male Universal Serial Bus (USB) connector for connecting the device to a host, a female USB connector for receiving the USB device, an integrated circuit, and a detector blocking the transmission of a device firmware update (DFU) from the host to USB device. | 03-29-2012 |